Skip to main content
BRKR
NASDAQ Industrial Applications And Services

Bruker Reports Q1 Results Ahead of Expectations, Reaffirms Full-Year Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$38.5
Mkt Cap
$5.786B
52W Low
$28.53
52W High
$56.22
52W Position info
35% above low
Off High info
32% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

BRKR sits 35% above its 52-week low of $28.53.

Summary

Bruker Corporation announced first-quarter 2026 financial results, exceeding expectations despite organic revenue decline, and reconfirmed its full-year 2026 revenue and non-GAAP EPS guidance.


Key Events · Earnings and Guidance · BRKR

  • Q1 2026 Financial Performance

    Reported Q1 2026 revenues of $823.4 million (up 2.7% year-over-year, down 4.4% organically) and non-GAAP diluted EPS of $0.31, with management noting performance was ahead of expectations.

  • Full-Year 2026 Guidance Reaffirmed

    Reconfirmed previous FY2026 guidance for revenues of $3.57 to $3.60 billion (4-5% year-over-year growth) and non-GAAP EPS of $2.10 to $2.15 (15-17% year-over-year growth), signaling confidence despite Q1 organic decline.

  • Strong Bookings Trend

    Bruker Scientific Instruments (BSI) segment bookings grew organically at a high-single digit percentage, with a book-to-bill ratio above 1.0x for the third consecutive quarter, indicating future revenue growth.


Analysis · BRKR · Industrial Applications And Services

Bruker Corporation announced first-quarter 2026 financial results, reporting revenues of $823.4 million, a 2.7% year-over-year increase, though organic revenue declined by 4.4%. GAAP diluted EPS was $0.02, while non-GAAP diluted EPS reached $0.31. Despite the organic revenue dip, management stated that financial performance came in ahead of expectations. Crucially, the company reconfirmed its full-year 2026 guidance, projecting revenues of $3.57 to $3.60 billion (4-5% year-over-year growth) and non-GAAP EPS of $2.10 to $2.15 (15-17% year-over-year growth). This reconfirmation, following a challenging 2025 with a net loss and impairment charges, provides a stabilizing signal. The Bruker Scientific Instruments (BSI) segment also reported high-single digit organic bookings growth and a book-to-bill ratio above 1.0x for the third consecutive quarter, indicating future revenue strength and a potential return to organic growth in Q2.

At the time of this filing, BRKR was trading at $38.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.8B. The 52-week trading range was $28.53 to $56.22. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BRKR - Latest Insights

BRKR
Jul 15, 2026, 7:03 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $58.97
Real-time Price: $62.84 info
Change: +$3.87 (+7%) info
Market Cap: $9.566B info
BRKR
Jun 12, 2026, 4:15 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $54.23
Real-time Price: $62.84 info
Change: +$8.61 (+16%) info
Market Cap: $9.566B info
BRKR
May 07, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $43.73
Real-time Price: $62.84 info
Change: +$19.11 (+44%) info
Market Cap: $9.566B info
BRKR
May 07, 2026, 4:09 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $44.00
Real-time Price: $62.84 info
Change: +$18.84 (+43%) info
Market Cap: $9.566B info
BRKR
Apr 10, 2026, 4:17 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $38.10
Real-time Price: $62.84 info
Change: +$24.74 (+65%) info
Market Cap: $9.566B info